743 reports of this reaction
3.8% of all ADO TRASTUZUMAB EMTANSINE reports
#2 most reported adverse reaction
FATIGUE is the #2 most commonly reported adverse reaction for ADO TRASTUZUMAB EMTANSINE, manufactured by Genentech, Inc.. There are 743 FDA adverse event reports linking ADO TRASTUZUMAB EMTANSINE to FATIGUE. This represents approximately 3.8% of all 19,599 adverse event reports for this drug.
Patients taking ADO TRASTUZUMAB EMTANSINE who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among ADO TRASTUZUMAB EMTANSINE users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for ADO TRASTUZUMAB EMTANSINE:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 743 FDA reports for ADO TRASTUZUMAB EMTANSINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 3.8% of all adverse event reports for ADO TRASTUZUMAB EMTANSINE, making it one of the most commonly reported side effect.
If you experience fatigue while taking ADO TRASTUZUMAB EMTANSINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.